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ABSTRACT Secretion of specific proteins contributes to pathogenesis and immune
responses in tuberculosis and other bacterial infections, yet the kinetics of protein
secretion and fate of secreted proteins in vivo are poorly understood. We generated
new monoclonal antibodies that recognize the Mycobacterium tuberculosis secreted
protein Ag85B and used them to establish and characterize a sensitive enzyme-
linked immunosorbent assay (ELISA) to quantitate Ag85B in samples generated in
vitro and in vivo. We found that nutritional or culture conditions had little impact on
the secretion of Ag85B and that there is considerable variation in Ag85B secretion
by distinct strains in the M. tuberculosis complex: compared with the commonly
used H37Rv strain (lineage 4), Mycobacterium africanum (lineage 6) secretes less
Ag85B, and two strains from lineage 2 secrete more Ag85B. We also used the ELISA
to determine that the rate of secretion of Ag85B is 10- to 100-fold lower than that
of proteins secreted by Gram-negative and Gram-positive bacteria, respectively.
ELISA quantitation of Ag85B in lung homogenates of M. tuberculosis H37Rv-infected
mice revealed that although Ag85B accumulates in the lungs as the bacterial popu-
lation expands, the amount of Ag85B per bacterium decreases nearly 10,000-fold at
later stages of infection, coincident with the development of T cell responses and
arrest of bacterial population growth. These results indicate that bacterial protein se-
cretion in vivo is dynamic and regulated, and quantitation of secreted bacterial pro-
teins can contribute to the understanding of pathogenesis and immunity in tubercu-
losis and other infections.
IMPORTANCE Bacterial protein secretion contributes to host-pathogen interactions,
yet the process and consequences of bacterial protein secretion during infection are
poorly understood. We developed a sensitive ELISA to quantitate a protein (termed
Ag85B) secreted by M. tuberculosis and used it to find that Ag85B secretion occurs
with slower kinetics than for proteins secreted by Gram-positive and Gram-negative
bacteria and that accumulation of Ag85B in the lungs is markedly regulated as a
function of the bacterial population density. Our results demonstrate that quantita-
tion of bacterial proteins during infection can reveal novel insights into host-
pathogen interactions.
KEYWORDS Ag85B, ELISA, bacterial antigen, bacterial protein secretion, monoclonal
antibodies, tuberculosis
Mycobacterium tuberculosis employs secretion of specific proteins (estimated toinclude up to 25% of the bacterial proteome [1]) to survive, interact with host
targets during infection (2, 3), manipulate its intracellular niche (2–7), and induce
protective and pathogenic immune responses (8). Among the proteins that are most
abundant in M. tuberculosis culture supernatants are members of a family of three
closely related proteins, the antigen 85 (Ag85) complex, consisting of Ag85A, Ag85B,
and Ag85C (9). All three of these proteins exhibit enzymatic activity as mycolyl
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transferases, in which they catalyze transesterification reactions to synthesize trehalose
monomycolate (TMM), trehalose dimycolate (TDM), and mycolated arabinogalactan (10,
11). Because of these enzymatic activities and their importance in constructing the
mycobacterial envelope, Ag85A, Ag85B, and Ag85C have been considered potential
drug targets for treatment of tuberculosis (TB) (10).
Due to their ability to induce adaptive CD4 and CD8 T lymphocyte responses in a
broad range of vertebrate hosts, Ag85A and Ag85B have been investigated as antigens
for tuberculosis vaccines and are prominent components of at least seven candidate
vaccines in various stages of development (http://www.aeras.org). Quantitative assays
of mRNA have revealed that the genes encoding Ag85A and Ag85B (fbpA and fbpB,
respectively) are expressed at high levels by bacteria in the lungs early after aerosol
infection of mice, but their mRNA expression decreases markedly after the recruitment
of antigen-specific effector T cells to the lungs (12–14). Consistent with the results of
bacterial RNA quantitation, CD4 T cells specific for Ag85B are activated in the lungs
between 2 and 3 weeks after infection of mice, but their activation markedly decreases
concurrent with decreased bacterial expression of the fbpB gene (12, 15).
Despite considerable knowledge of the properties of the fbpA and fbpB genes and
the antigenicity of their products, there is less information on the secretion, in vivo
expression, and trafficking of the Ag85A or Ag85B proteins. Because of interest in
Ag85B as a vaccine and/or diagnostic antigen, we generated new monoclonal anti-
bodies (mAbs) to Ag85B and used them to establish a highly sensitive and specific
enzyme-linked immunosorbent assay (ELISA). We then employed the ELISA in studies of
secretion and trafficking of the Ag85B protein in vitro and in vivo.
RESULTS
Generation and characterization of monoclonal antibodies to Ag85B. Monoclo-
nal antibodies were generated, using standard methods (16), from mice immunized
with purified recombinant M. tuberculosis Ag85B (rAg85B) expressed in Escherichia coli.
Three mAbs, termed 710, 711, and 712, were selected for characterization. When
examined by a direct ELISA using wells coated with purified rAg85A, rAg85B, or rAg85C
and various concentrations of antibody, all three mAbs recognized Ag85B and yielded
equivalent signals (Fig. 1A). The three mAbs also recognized Ag85A in the direct ELISA,
although recognition of Ag85A required higher antibody concentrations and reached
a lower maximum signal intensity than with Ag85B. mAb 710 generated a higher signal
intensity and at lower antibody concentrations than with mAbs 711 and 712; the latter
two mAbs also exhibited detectable binding to Ag85A when used at concentrations of
1 g/ml (Fig. 1B). In contrast, mAbs 711 and 712 did not bind to Ag85C in the direct
ELISA at any antibody concentration examined, while mAb 710 bound Ag85C at
antibody concentrations as low as 0.01 g/ml (Fig. 1C). Testing of the mAbs at a fixed
concentration of 1 g/ml on a dilution series of recombinant protein in the direct ELISA
revealed that mAb 710 bound to Ag85A, Ag85B, and Ag85C at lower antigen concen-
trations than did mAb 711 or 712; mAbs 711 and 712 were indistinguishable in this
assay. All three mAbs bound to Ag85B at lower antigen concentrations than required
for binding to Ag85A or Ag85C (Fig. 1D and E). Together, these results indicate that
mAbs 710, 711, and 712 preferentially recognize Ag85B, although each of the mAbs
also binds Ag85A and Ab85C when these antigens are present at high concentrations.
Sandwich ELISA for quantitation of Ag85B. When the three mAbs were used in
pairwise combinations, using one mAb for capture and another mAb conjugated to
horseradish peroxidase (HRP) for detection of bound antigen, the highest sensitivity for
detection of Ag85B was obtained when mAb 710 was used as the capture antibody
(Fig. 2A). Although the differences were slight, sensitivity appeared to be greater when
mAb 711 rather than mAb 712 was used as the detection antibody. Compared with
Ag85B capture by mAb 710, mAb 711 capture allowed detection of bound Ag85B by
mAb 710 but not by mAb 712. When mAb 712 was used for capture, mAb 710 was able
to bind Ag85B, but mAb 711 was not. Together, these data indicate that the epitopes
recognized by mAbs 711 and 712 overlap or may even be identical, while the epitope
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recognized by mAb 710 is distinct from those of mAbs 711 and 712. Despite detectable
binding of all three mAbs to Ag85A in the direct ELISA (Fig. 1B), none of the combi-
nations of capture or detecting antibodies yielded a signal when Ag85A was used as
the antigen in the sandwich ELISA (Fig. 2B). Likewise, despite binding of mAb 710 to
Ag85C by the direct ELISA, none of the capture or detection antibody combinations
resulted in a detectable signal in the sandwich ELISA when Ag85C was used as the
antigen (Fig. 2C). Together, these results suggest that the epitope recognized by mAb
710 is at least partially shared by Ag85A, Ag85B, and Ag85C, while the epitope(s)
recognized by mAbs 711 and 712 is more specific to Ag85B.
To confirm the specificity of the ELISA with the combination of mAbs 710 and 711
using native M. tuberculosis proteins, we examined culture filtrates of wild-type H37Rv
and of our previously characterized Ag85B-deficient (fbpB-null) mutant strain of H37Rv
(12). This yielded no detectable signal in the ELISA when culture filtrates of the
Ag85B-deficient bacteria were examined, despite the detection of an abundant signal
when wild-type culture filtrates were examined (Fig. 2D). Since the Ag85B-null bacteria
retain the capacity to synthesize and secrete Ag85A and Ag85C (17), these results
provide further evidence that the sandwich ELISA with mAbs 710 and 711 is highly
specific for Ag85B.
The assay in this form, with mAb 710 as the capture antibody and HRP-coupled mAb
711 as the detection antibody, has been run in our laboratory 30 times to determine
Ag85B content in various samples. Each assay comprised at least one standard
curve with rAg85B per ELISA plate, starting at 10 ng/ml or above and including
2-fold dilutions to loss of signal (generally, 20 pg/ml). Three representative assay
standard curves are shown in Fig. 2E. Ag85B in samples was quantitated based on
either a dose-response sigmoidal regression curve or a linear regression in the linear
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FIG 1 Recognition of Ag85A, Ag85B, and Ag85C by monoclonal antibodies 710, 711, and 712. (A to C) Wells of 96-well plates were coated with Ag85B (A),
Ag85A (B), or Ag85C (C), each at 0.5 g/ml. mAb 710, 711, or 712 was added at the indicated concentrations, and binding was detected after washing, using
HRP-conjugated goat anti-mouse IgG and the TMB substrate. Data shown in panels A to C are representative of results from three independent experiments
with one technical replicate per experiment per condition. (D to F) Individual wells were coated with a dilution series of Ag85B (D), Ag85A (E), or Ag85C (F),
starting at 20 g/ml. mAb 710, 711, or 712 was added at a concentration of 1 g/ml, and binding was detected after washing, using HRP-conjugated goat
anti-mouse IgG and the TMB substrate. Data in panels D to F are representative of results from two independent experiments with one technical replicate per
experiment per condition.
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proportion of the curve (0 ng/ml to 2.5 ng/ml). With both methods, regression curves
had R2 values of 0.99. When necessary, samples were diluted for the ELISA to be in
the linear range of the standard curve, and at least two technical replicates or biological
replicates (when available) were run.
Carbon source effects, strain-dependent variation, and kinetics of Ag85B se-
cretion. We used the ELISA to examine whether Ag85B secretion is governed by
bacterial growth conditions. When grown in rich broth (Middlebrook 7H9 medium with
10% albumin-dextrose-catalase [ADC]), a 10-fold difference in the Tween 80 concen-
tration (0.5% versus 0.05%) did not affect the amount of Ag85B secreted by M.
tuberculosis H37Rv over a 24-h period (Fig. 3A). When H37Rv was grown in minimal
defined medium (Sauton’s medium with 0.05% Tween 80, 0.5% bovine serum albumin
[BSA], and 0.05% tyloxapol) or 7H9 broth with the addition of 0.2% acetate, dextrose,
or glycerol as the carbon source, the addition of acetate or glycerol did not alter Ag85B
secretion, whereas 0.2% dextrose increased Ag85B secretion approximately 2-fold
(Fig. 3A). These results indicate that bacterial metabolism as dictated by alternative
carbon sources can affect the rate and/or amount of Ag85B secretion but that the
concentration of Tween 80 had little measurable effect.
We previously reported that Mycobacterium africanum expresses lower levels of
Ag85B than M. tuberculosis H37Rv, as detected by immunoblotting and by the magni-
tude of in vivo antigen-specific CD4 T cell responses (18). To verify this result and
determine whether other strain-dependent variation in Ag85B secretion exists, we used
the Ag85B-specific ELISA to assay culture filtrates from phylogenetically distinct bac-
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FIG 2 Characterization of the sandwich ELISA for Ag85B. Each mAb was tested as the capture antibody, with either of the remaining two mAbs (conjugated
to HRP) used for detection. (A) Detection of rAg85B added to mAb-coated plates at the concentrations indicated on the x axis. (B) Detection of rAg85A under
the same conditions as described above for panel A. The inset shows the same data on a contracted scale to reveal small differences. (C) Detection of rAg85C
under the same conditions as described above for panel A. The inset shows the same data on a contracted scale to reveal small differences. (D) Specificity of
the ELISA using mAb 710 for capture and HRP-conjugated mAb 711 for detection of antigen in culture filtrates of wild-type M. tuberculosis H37Rv or M.
tuberculosis H37Rv with a targeted deletion of the gene encoding Ag85B. The H37Rv culture filtrate was diluted to give a signal in the linear range of the ELISA
standard curve, while the H37RvΔAg85B culture filtrate was assayed undiluted. The date shown are means (bars) and standard deviations (error bars) of
biological triplicate values. OD, optical density. (E) Standard curves of rAg85B in an Ag85B ELISA. Shown are curves from three independent experiments with
two independent standard curves each. Shown are means (dots) and standard deviations (error bars) when large enough to depict. Data shown in panels A
to C are representative of results from three independent experiments with one technical replicate per experiment per condition.
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terial isolates. This confirmed that M. africanum secretes significantly smaller quantities
of Ag85B than M. tuberculosis H37Rv (Fig. 3B). We also found that two distinct isolates
of M. tuberculosis from lineage 2 (which includes the Beijing family) secrete significantly
larger quantities of Ag85B than H37Rv (Fig. 3B). These results indicate substantial
variation in the secretion of Ag85B, according to the bacterial strain, possibly in a
lineage-dependent manner.
To further characterize the properties of Ag85B, we determined the kinetics of its
secretion by M. tuberculosis H37Rv. Washed mid-log-phase bacteria were suspended in
fresh 7H9 medium at 108 CFU/ml, and culture filtrates were harvested at multiple
intervals and assayed by an ELISA. The rate of accumulation of Ag85B in culture filtrates
was linear (r2  0.93) during the 24-h period of sampling, at 1.8 0.2 ng/ml/h (Fig. 3C).
Since the mature Ag85B protein has a molecular weight of 34,580, this is equivalent to
52 fmol per 108 CFU per h, or approximately 300 molecules secreted per bacterial cell
per h.
Cell-free Ag85B during infection in vivo and in vitro. Despite their biological
activity and roles in pathogenesis and immune responses, little is known of the in vivo
fate or distribution of secreted M. tuberculosis proteins, especially during infection.
Therefore, we examined supernatants of lung homogenates obtained at various inter-
vals after infecting C57BL/6 mice with M. tuberculosis H37Rv by aerosol. We found that
Ag85B was detectable in lung homogenate supernatants in some, but not all, mice as
early as 4 to 8 days postinfection, followed by a progressive increase between 14 and
21 days postinfection (Fig. 4A). Since the samples for the assay were taken during the
progressive growth phase of the bacteria in the lungs, the quantity of Ag85B detected
is a function of the amount secreted by each bacterium and the number of bacteria,
which increases progressively until approximately 21 days postinfection (19). Therefore,
we normalized the concentration of Ag85B in lung homogenates by the number of
bacteria present in the lungs at each time point sampled. This revealed a progressive
decrease in the amount of Ag85B relative to the bacterial population size, commencing
at between 8 and 11 days postinfection (Fig. 4B). This result is consistent with results of
Ag85B RNA quantitation in bacterial populations in the lungs of immunocompetent
mice (12–14) and with results of studies indicating that activation of Ag85B-specific CD4
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secretion. Mid-log-phase bacteria (A600  1.0) grown in 7H9 medium were washed 5 times and then diluted 10-fold into the indicated media. After 24 h, the
A600 was determined for each culture, and sterile filtrates were prepared for analysis by a mAb 710-711 ELISA. Results of Ag85B quantitation by the ELISA were
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effects were not significant after adjusting for multiple comparisons. (B) Mycobacterial strain-dependent variation of Ag85B secretion. Mid-log-phase cultures
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Ag85B in culture filtrates was quantitated by an ELISA. Show are means (bars) and standard deviations (error bars) of biological triplicate values. The adjusted
P values shown are for comparison of each strain with H37Rv and were determined by one-way ANOVA with Dunnett’s posttest. (C) Kinetics of Ag85B secretion
by M. tuberculosis H37Rv. Mid-log-phase growing H37Rv cells were washed, added to fresh 7H9 medium at 1 108 CFU/ml, and incubated for 24 h. Individual
cultures were sampled at the designated time points, and culture filtrates were assayed by an ELISA. Statistical analysis by linear regression was performed using
Prism 7. Dashed lines indicate 95% confidence intervals. Panel A shows data from one representative of three independent experiments. Panels B and C show
data from experiments done once each.
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T cells in vivo decreases markedly after 2 to 3 weeks of infection, due to the limited
availability of the antigen (12, 15).
There are several potential sources of free Ag85B in the lungs. First is that some of
the bacteria may be extracellular and may secrete Ag85B directly to the intercellular
spaces in lung tissues. Second is that, as we have recently reported, Ag85B and other
secreted mycobacterial proteins can be exported from infected cells by a vesicular
transport pathway (20, 21). A third potential mechanism is the release of Ag85B
associated with bacterial membrane vesicles (22) and/or exosomes shed by infected
cells (23, 24). A fourth possible mechanism is that Ag85B synthesized by intracellular
bacteria may be released from dying infected cells. We investigated the latter possibility
using bone marrow-derived dendritic cells (BMDC) infected with M. tuberculosis H37Rv.
Under conditions of the multiplicities of infection, bacterial strain, and time points used,
we observed a range of loss of cell viability as reflected by a luminescence assay of ATP
in cell lysates, after harvesting conditioned medium for the assay of Ag85B by an ELISA.
This revealed a correlation between the loss of cell viability and the quantity of Ag85B
in conditioned medium (r2  0.5777; P 0.0001) (Fig. 5), indicating that Ag85B can be
released from dead and/or dying infected cells in a form that remains detectable by the
ELISA. This suggests that death of infected cells can be a source of the Ag85B detected
in cell-free homogenates of the lungs of infected mice, as shown in Fig. 4.
DISCUSSION
In this work, we developed three new murine monoclonal antibodies by immunizing
mice with recombinantM. tuberculosis Ag85B and used them to develop a sensitive and
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FIG 4 Quantitation of Ag85B in supernatants of lung homogenates from mice infected with M. tuberculosis H37Rv. (A) M. tuberculosis CFU in the lung samples
used for assays in panel B. (B) Ag85B concentrations quantitated by an ELISA in lung homogenate supernatants; (C) Ag85B concentrations as described above
for panel B, normalized by the number of bacteria (CFU) in the same lung homogenates. Shown are individual data points (means  standard deviations). This
experiment was done once.
0 25 50 75 100
0.01
0.1
1
10
Loss of viability (%)
Ag
85
B 
in
 m
ed
ia
 (n
g/
m
l)
FIG 5 Death of M. tuberculosis-infected primary dendritic cells releases Ag85B. Bone marrow-derived
dendritic cells were infected with M. tuberculosis H37Rv at different multiplicities of infection (1, 2, 4, and
8). At the designated time points (gray dots, 12 h; medium blue dots, 16 h; red dots, 24 h; light blue dots,
36 h; dark blue dots, 48 h), medium was removed for quantitation by an ELISA, and dendritic cell viability
was assessed by a luminescence assay of ATP of cell lysates. Results of the two assays on a given sample
were plotted as a data point, and Pearson correlation was determined for the whole data set. Shown are
representative results of two similar experiments.
Ernst et al. ®
March/April 2019 Volume 10 Issue 2 e00611-19 mbio.asm.org 6
specific ELISA for quantitation of Ag85B in various biological samples. We found that,
compared with the H37Rv strain of M. tuberculosis complex lineage 4, two isolates of
lineage 2 secreted large quantities, while a lineage 6 (M. africanum) isolate secreted
small quantities, of Ag85B. Since Ag85B plays a role in the synthesis of trehalose
dimycolate, and trehalose dimycolate is a potent proinflammatory mediator during M.
tuberculosis infection (25–28), the results suggest that differences in Ag85B secretion
may contribute to strain-dependent differences in the proinflammatory properties of
distinct strains and lineages in the M. tuberculosis complex (29). Strain variability in
secretion may also influence the frequency and magnitude of T cell responses to
Ag85B, which may provide an explanation for the finding that few human subjects
exhibit detectable responses to Ag85B compared with other antigens such as ESAT-6
and/or CFP-10 (30, 31). Likewise, bacterial strain-dependent variation in the secretion of
Ag85B may influence the protective efficacy of TB subunit vaccines that include Ag85B:
even if a vaccine generates immune responses to Ag85B, vaccination may provide little
protection against infection with mycobacterial strains that express and secrete small
quantities of Ag85B. In studies of subunit vaccines that include Ag85B, it may be
informative to characterize Ag85B expression and secretion in isolates ofM. tuberculosis
from subjects who develop breakthrough infections despite apparently appropriate
immune responses to the vaccine antigen.
We also used the ELISA to determine that the rate of secretion by M. tuberculosis
H37Rv in broth culture is approximately 300 molecules of Ag85B per bacterial cell per
h. This is 10- to 100-fold lower than the rate of translocation of E. coli proOmpA
(4.5 mol/min) (32) or the secretion of staphylococcal toxic shock toxin (1.1 104
molecules/CFU/h) (33). A full understanding of the basis for this difference will require
determination of the rates of protein synthesis in M. tuberculosis compared with those
in other bacteria and characterization of the factors and mechanisms that determine
the rate of protein secretion by distinct secretion systems in bacteria. Given the
important roles of secreted protein virulence factors in M. tuberculosis and other
bacterial pathogens, a better understanding of protein secretion may reveal new
targets for therapeutic modulation and reduction of disease and pathogen transmis-
sion.
A third major finding in these studies is that M. tuberculosis Ag85B can be found in
homogenized lung tissue supernatants from infected mice. This finding has several
potential implications. If data from studies of human subjects provide supportive data,
then detecting Ag85B in respiratory secretions may provide a rapid and economical
approach to diagnosing pulmonary tuberculosis and may also be useful in monitoring
responses to treatment. Another is that the presence of extracellular Ag85B in lung
tissue may make Ag85B available for uptake, processing, and presentation by unin-
fected dendritic cells and macrophages in the lungs. Since we have reported that direct
recognition of infected cells is required for optimal CD4 T cell control of intracellular M.
tuberculosis (34), acquisition and presentation of Ag85B by uninfected cells in the lungs
may provide antigen-loaded decoys for Ag85B-specific CD4 T cells that reduce the
frequency of recognition of infected cells by those T cells. This is consistent with our
recent finding in mouse lungs (35) and the finding in lungs of M. tuberculosis-infected
rhesus macaques (36) that only a small fraction of the T cells in the lungs are in close
contact with M. tuberculosis-infected cells. Our associated finding in this work that
death of M. tuberculosis-infected host cells can be associated with the release of Ag85B
to the extracellular space indicates that the presence of Ag85B (and other mycobac-
terial proteins) in extracellular tissue compartments in the lungs may be the conse-
quence of secretion by extracellular bacteria, vesicular transport from infected cells (21),
carriage by exosomes (37, 38), and release by dying or dead host cells. Since Ag85B (39,
40), ESAT-6 (41), and other mycobacterial proteins have been reported to act on host
cells to modulate inflammation, our findings provide additional evidence for the
plausibility that extracellular mycobacterial proteins contribute to the pathogenesis of
TB and may be susceptible to therapeutic modulation.
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MATERIALS AND METHODS
Ethics statement. All animal experiments were done in accordance with procedures approved by
the New York University School of Medicine Institutional Animal Care and Use Committee (laboratory
animal care protocol 150502-01), which conformed to the guidelines provided by the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health (42).
Bacterial strains. The stocks of M. tuberculosis H37Rv, H37Rv::ΔfbpB (Ag85B null), and 4334 and M.
africanum 1182 used in our laboratory and for these studies were previously described (19, 43–45). The
M. tuberculosis HN878 strain was obtained from BEI Resources.
Recombinant Ag85B. RV1886c-ss.pET23b was transformed into E. coli BL21(DE3)/pLysS (Invitrogen)
and induced with 0.8 mM isopropyl--D-thiogalactopyranoside (IPTG) for 4 h at 37°C. Cultures were lysed
with a solution containing 50 mM Tris (pH 7.0), 150 mM NaCl, lysozyme, Benzonase, and 1 mM phenyl-
methylsulfonyl fluoride (PMSF) for 30 min at 22°C on an orbital shaker. The lysate was spun at 10,000 g
for 30 min, sterile filtered, and loaded onto an Akta fast protein liquid chromatography (FPLC) His-Trap
column (GE). The column was washed with 50 mM imidazole, and recombinant protein was eluted with
250 mM imidazole. Purity was assessed by SDS-PAGE.
mAb generation and selection. BALB/c mice were immunized with purified recombinant Ag85B
(100 g/mouse for 2 injections followed by 50 g/mouse for 2 additional injections) subcutaneously in
TiterMax gold (TiterMax, Norcross, GA, USA), followed by 50 g/mouse given intravenously 3 days before
harvesting and using spleen cells in fusions with P3X63Ag8 myeloma cells. Hybridoma supernatants were
screened for recognition of rAg85B-coated wells by an ELISA.
Direct ELISA for characterization of individual mAbs. Ag85A (catalog number NR-14871; BEI
Resources), Ag85B (our purified recombinant), or Ag85C (catalog number NR-14858; BEI Resources) was
used to coat wells at 0.5 g/well in phosphate-buffered saline (PBS) and incubated overnight at 4°C. The
plates were washed 3 times with PBS (pH 7.4) with 0.05% Tween 20 and blocked with PBS containing
1.0% BSA for 1 h. A starting concentration of 5 g/ml of mAb 710, 711, or 712 was serially diluted, and
200 l/well was incubated at room temperature for 2 h. Plates were washed 5 times and incubated with
goat anti-mouse IgG-HRP (MP Biomedicals) for 1 h at room temperature. Plates were washed 7 times and
developed with the 3,3=,5,5=-tetramethylbenzidine (TMB) substrate according to the manufacturer’s
instructions (BD). The reaction was stopped with 2 M sulfuric acid, and the absorbance was read at
450 nm with a Synergy H1 microplate reader (BioTek).
Mycobacterial culture filtrates. M. tuberculosis strains H37RV, 4334, and HN878, or M. africanum
strain 1182, were inoculated from a 1-ml frozen stock of approximately 3 108 CFU/ml into 10 ml of
Middlebrook 7H9 medium supplemented with 0.5% albumin, 0.2% dextrose, and 0.3 mg/100 ml catalase
(termed 7H9 in the text) and grown to late log phase. The cultures were then passaged and grown once
to mid-log phase. Cultures were then collected and spun at 150 g. The collected supernatant was then
spun at 3,750 g for 5 min and washed with PBS. The pellets were then resuspended in fresh 7H9
medium and grown for 24 h. The cultures were pelleted, and the medium was sterile filtered.
Sandwich ELISA development and optimization. Individual mAbs were used at 2.5 g/ml in 50 l
0.05 M carbonate-bicarbonate buffer to coat wells overnight at 4°C. The plates were washed 3 times with
PBS (pH 7.4) with 0.5% Tween 20 and blocked with PBS containing 1.0% BSA for 1 h. Antibodies for
detection were conjugated to HRP according to the manufacturer’s recommendations (Abcam). Briefly,
1 l of the modifier was mixed with 10 l of antibody and then added to a vial of HRP mix. The vial was
incubated overnight at room temperature in the dark. After incubation, 1 l of the quencher was added
and mixed. The conjugated antibodies were diluted to 0.5 g/ml in PBS with 1% BSA and stored in
aliquots at 20°C until first use. Upon thawing, conjugated antibodies were stored at 4°C.
For ELISAs, samples were added to plates coated with the designated antibody and incubated at
room temperature for 2 h, and plates were then washed 5 times. The labeled detection antibody was
added, and the plates were incubated at room temperature for 1 h. Plates were washed 7 times and
developed with the substrate according to the manufacturer’s instructions (BD). The reaction was
stopped with 2 M sulfuric acid, and the absorbance was read at 450 nm.
Sandwich ELISA application. The routine sandwich ELISA was performed according to the proce-
dures described above, with mAb 710 as the capture antibody used to coat wells and HRP-conjugated
mAb 711 used to detect bound antigen. Signal generation for the HRP reaction was done by using the
TMB substrate (Thermo Scientific).
Effects of medium and carbon source. After washing in PBS, bacteria were resuspended in 6 ml of
distilled water and split among 6 bottles. Ten milliliters of medium was added to the bottles. The medium
used was Middlebrook 7H9 medium with 10% ADC and either 0.05% or 0.5% Tween 80 or Sauton’s broth
with 0.05% Tween 80, 0.5% BSA, 0.05% tyloxapol, and 0.2% (wt/vol) acetate, glycerol, or dextrose
(adapted from reference 46), and bacteria were incubated for 24 h prior to preparation of culture filtrates.
Preparation of lung homogenate supernatants from M. tuberculosis-infected mice. C57BL/6
mice were infected by the aerosol route with 60 CFU/mouse of M. tuberculosis H37Rv, lungs were
harvested, and single-cell suspensions were prepared as previously described (47). After sampling the cell
suspensions for determination of bacterial CFU, an aliquot of each sample was sterile filtered, and the
Ag85B concentration was determined by an ELISA.
Culture, infection, and analysis of bone marrow-derived dendritic cell death and release of
Ag85B. Bone marrow-derived dendritic cells (BMDC), generated as previously described (20), were
seeded in 96-well tissue culture-treated plates (Corning) at 2 106 cells/well, rested for 2 h, infected
overnight at different multiplicities of infection (1, 2, 4, and 8) with M. tuberculosis H37Rv, treated with
amikacin (200 g/ml for 40 min) in BMDC medium (RPMI 1640 supplemented with 10% heat-inactivated
fetal bovine serum [FBS], 2 mM L-glutamine, 1 mM sodium pyruvate, 1 -mercaptoethanol, 10 mM
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HEPES, and 12 ng/ml recombinant mouse granulocyte-macrophage colony-stimulating factor [GM-CSF]),
washed three times in PBS, and further cultured in fresh BMDC medium. Conditioned medium (CM) was
harvested 16, 24, 34, and 48 h later and sterile filtered, and Ag85B in CM was quantified by a sandwich
ELISA. At each harvest time point, infected BMDC were assayed for cell death by using CellTiter-Glo
(Promega) according to the manufacturer’s instructions, and the signal was read as luminescence with
a Synergy H1 microplate reader (BioTek). For each harvest time point, the signal from uninfected cells
was considered 100% viability for determination of loss of viability of infected cells.
Statistical analyses. All statistical analyses were performed using Prism 7 (GraphPad). The specific
tests used for data analysis are specified in the individual figure legends.
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